Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

Daniel Kim Views  

Medical Today
Medical Today

Merck & Co. recently revealed its intention to introduce a subcutaneous version of Keytruda, its cancer immunotherapy, to the US market on October 1. The subcutaneous formulation of Keytruda is still awaiting approval from the U.S. Food and Drug Administration (FDA), with a decision expected by September 23.

Merck explained that administering Keytruda via subcutaneous injection, as opposed to intravenous infusion, could significantly reduce the time patients spend receiving treatment.

Merck’s Senior Vice President of Oncology stated in an interview that they plan to ship the product immediately following approval, ensuring sufficient supply to meet market demand within 1-2 weeks.

Keytruda, approved for treating various types of cancer, is currently the world’s best-selling prescription drug. Sales are projected to reach approximately $30 billion in 2024.

Industry experts predict that Merck, which has relied heavily on Keytruda for growth in recent years, could benefit from intellectual property protection for the subcutaneous version before Keytruda’s primary patent expires in 2028. Alteogen, a South Korean pharmaceutical company, is developing and manufacturing an enzyme used in the subcutaneous formulation of Keytruda.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Food Addiction in Kids Tied to Low Self-Esteem and Poor School Performance
  • Baby’s Here, But the Weight’s Still There? You’re Not Alone
  • Inside the Pope’s Health Crisis: Antibiotic-Resistant Infection Fuels Global Concern
  • Want to Lose Weight? Trick Your Brain with These Simple Diet Hacks!
  • Turns Out, What You Eat at 40 Really Can Shape How You Feel at 70
  • FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections